AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Junction plakoglobin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P14923

UPID:

PLAK_HUMAN

Alternative names:

Catenin gamma; Desmoplakin III; Desmoplakin-3

Alternative UPACC:

P14923; Q15093; Q15151; Q7L3S5; Q86W21; Q9BWC4; Q9HCX9

Background:

Junction plakoglobin, also known as Catenin gamma, plays a pivotal role in cell adhesion and signal transduction. It is a key component of desmosomes and adherens junctions, facilitating the connection between the cytoskeleton and the cell membrane. This protein's ability to replace beta-catenin in E-cadherin/catenin adhesion complexes underscores its versatility and importance in cellular cohesion and communication.

Therapeutic significance:

Junction plakoglobin's involvement in Naxos disease and Arrhythmogenic right ventricular dysplasia, familial, 12, highlights its clinical relevance. These conditions, characterized by cardiac abnormalities and skin disorders, underscore the protein's potential as a therapeutic target. Understanding the role of Junction plakoglobin could open doors to potential therapeutic strategies, offering hope for patients suffering from these genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.